Bristol-Myers Squibb and AstraZeneca
ONGLYZA(TM) (saxagliptin) With Metformin As Initial Combination Therapy Provided 76-Week Long-Term Glycemic Control In Treatment-Naive Adults With Type 2 Diabetes
Orlando, Florida, June 26, 2010 (ots/PRNewswire) - Bristol-Myers Squibb Company and AstraZeneca today announced results up to 76-weeks from a Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy with metformin, which produced long-term glycemic improvement [as measured by glycosylated ...